Rating Change
Guggenheim analysts reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) on July 09, 2026.
reiterateNYSE:ABBV
Guggenheim Reiterates Buy Rating on AbbVie Inc. (ABBV)
Rating Change Guggenheim analysts reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) on July 09, 2026. Market Context AbbVie Inc.
Market Context
AbbVie Inc. operates in the Healthcare sector. The stock currently trades at $249.91 with a market capitalization of $410.1B. The stock has gained 15.4% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for AbbVie Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for AbbVie Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 09, 2026 | Guggenheim | Buy | N/A |
| Jul 09, 2026 | JP Morgan | Overweight | N/A |
| Jul 06, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jun 23, 2026 | Piper Sandler | Overweight | N/A |
| Jun 23, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ABBV Stock Page
Frequently Asked Questions
What does a Buy rating mean for ABBV?
A Buy rating from Guggenheim reflects the analyst's outlook on AbbVie Inc. (NYSE:ABBV). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ABBV forecast page.